Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.80 +0.03 (+0.10%)
Streaming Delayed Price Updated: 2:37 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Forget Medical Properties Trust: This High-Yielding Dividend Stock Is a Much Better Buy
Medical Properties Trust's yield looks appealing, but it wouldn't have made up for the stock's 70% decline over the last three years. 
Via The Motley Fool
7 High-Yield Dividend Stocks Beating Inflation
High-yield dividend stocks are one of the surest paths to beating inflation as the cost of everything remains high in mid-2024. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Decoding Pfizer's Options Activity: What's the Big Picture?
Via Benzinga
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
Why Pfizer Stock Is Moving Higher on Thursday
Pfizer announced it will advance development of its once-daily Danuglipron. 
Via Benzinga
Pfizer Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector. 
Via InvestorPlace
2 Pharma Stocks to Buy Hand Over Fist This Month
These drugmakers may not be in perfect health right now, but that shouldn't last much longer. 
Via The Motley Fool
Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
Inflation drops, speculations rise on interest rate cuts. Producer inflation data fails to alter expectations, tech sector underperforms. 
Via Benzinga
Topics Economy
Exposures Interest Rates
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position. 
Via Talk Markets
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with dose optimization studies planned for late 2024. The study will evaluate... 
Via Benzinga
Pfizer, L3Harris Technologies And More: CNBC's 'Final Trades'
Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study. 
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector. 
Via Benzinga
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
Wall Street Weighs In As Pfizer Targets $100 Billion Weight Loss Market
Pfizer announced plans to advance a once-daily version of its weight loss pill, danuglipron, following encouraging early-stage trial results. 
Via Talk Markets
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
Pfizer advances its once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, after positive Phase 1 pharmacokinetic study results. Dose optimization studies will follow... 
Via Benzinga
Pfizer Stock Jumps After Picking Daily Pill As Weight-Loss Drug
The company now plans to run multiple tests of the drug, danuglipron, to determine the right dose for registration-enabling studies. 
Via Investor's Business Daily
Premarket Stocks: 3 Fast Movers And 1 In A Buy Zone
Several stocks angled higher early Thursday with one in a buy zone and two looking to reclaim key levels. 
Via Investor's Business Daily
7 High-Yield Dividend Stocks to Buy and Hold Forever: July Edition
Explore the top seven high-yield dividend stocks, leading in several industries to buy and hold for income stability. 
Via InvestorPlace
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
Hercules Capital, Pfizer and Target offer stability, growth potential and reliable dividends in the realm of high-dividend stocks. 
Via InvestorPlace
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
From Pfizer Inc.
Via Business Wire
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
Via InvestorPlace
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. 
Via Benzinga
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
Q2 estimates have been stable heading into earnings season, potentially setting a lower bar for corporations to beat analyst expectations and surprise to the upside. 
Via Talk Markets
Topics Stocks
Exposures US Equities
3 No-Brainer Stocks to Buy With $100 Right Now
You don't need a mountain of cash to grow your wealth on Wall Street. 
Via The Motley Fool
Pfizer Launches Process To Identify Chief Scientific Officer Successor
Pfizer announced its starting the process to find a new chief scientific officer and president of Pfizer Research and Development. 
Via Benzinga
The 3 Most Undervalued Large-Cap Stocks to Buy in July 2024
Looking for standout picks this summer? These three undervalued large-cap stocks to buy now are compelling opportunities. 
Via InvestorPlace
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
Via Investor Brand Network
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
Via InvestorPlace
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.